Stem cell historical CryoSave's core business now profitable and improving
Consolidated operations, headcount rationalization, integrated sales and marketing strategies, laboratories integration and processes automatization completed to yield enhanced performance and results
Zutphen,The Netherlands-17March 2015
Frederic Amar, appointed ESPERITE CEO on March 2014, is implementing from the onset an aggressive reorganization and development of the company. Frederic Amar's far-reaching new business model has materialized in three separate synergetic business units attacking new markets with a diversified offer, transforming a mono-product business model into a biotech multiservice company. ESPERITE's consolidated operations feature now reduced complexity, sustainable lower overhead, centralized administrative services, integrated sales and marketing strategies coupled with the technology to handle large volumes efficiently. The preliminary (unaudited) financial results for year ended 31 December 2014 published today reflect these improvements.
Frederic Amar, CEO of ESPERITE: "ESPERITE, both an aspiration and inspiration, reborn on July 2014 to signal a whole new way of doing business and create growth. It was a year of strong impulse and fierce implementation of new ideas. Execution exceeded expectations and results will too. I am proud of our achievements this year transforming a fragile company into an ambitious start-up. Our strategic investments and mastery of technology brings ESPERITE to pole position".
Financial highlights
Revenue 27.6 million (2013: 29.8 million) Gross profit as percentage of revenue 62.2% (2013: 64.5%) Underlying* operating expenses before depreciation, amortization and impairments: 17.7 million (2013: 18.7 million) Underlying EBITDA**: -0.56 million (2013: 0.5 million)
Underlying EBITA***: -2.1 million (2013: -1.0 million) Underlying operating result: -3.4 million (2013: -2.3 million)
Read the original here:
ESPERITE (ESP) financial results for 2014 published, metamorphosis completed, first positive forecast growth at 36mio ...